This paper aims to summarize the contributions of Richard Guy and collaborators to the skin field. Major contributions have been areas such as the modelling of skin absorption, use of spectroscopic techniques (Fourier transform infrared spectroscopy, attenuated total reflectance Fourier transform infrared spectroscopy and impedance spectroscopy) to characterize the skin barrier and the effects of enhancing techniques on the membrane, dermatopharmacokinetics and assessment of topical bio-availability, iontophoresis and reverse iontophoresis, and use of imaging techniques to elucidate pathways of penetration and the skin disposition of nanoparticles. The field of topical and transdermal drug delivery has benefitted incalculably from the extensive work of Guy and his group: their findings about mechanisms of drug delivery and permeation enhancement, and the development of methodologies which are now accepted as gold standards by skin scientists.

1.
Scopus author search. http://www.scopus.com/authid/detail.url?authorId=7201580157 (accessed December 20, 2012).
2.
Researcher ID. Thomson Reuters. http://www.researcherid.com/rid/H-3471-2012 (accessed December 20, 2012).
3.
Potts RO, Guy RH: Predicting skin permeability. Pharm Res 1992;9:663-669.
4.
Alvarez-Roman R, Naik A, Kalia Y, Guy RH, Fessi H: Skin penetration and distribution of polymeric nanoparticles. J Control Release 2004;99:53-62.
5.
Potts RO, Guy RH: A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm Res 1995;12:1628-1633.
6.
Naik A, Pechtold LARM, Potts RO, Guy RH: Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Release 1995;37:299-306.
7.
Bommannan D, Potts RO, Guy RH: Examination of stratum corneum barrier function in vivo by infrared spectroscopy. J Invest Dermatol 1990;95:403-408.
8.
Delgado-Charro MB, Iglesias-Vilas G, Blanco-Méndez J, López-Quintela MA, Marty J, Guy RH: Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur J Pharm Biopharm 1997;43:37-42.
9.
Kalia YN, Pirot F, Guy RH: Homogeneous transport in a heterogeneous membrane: water diffusion across human stratum corneum in vivo. Biophys J 1996;71:2692-2700.
10.
Mehier-Humbert S, Bettinger T, Yan F, Guy RH: Plasma membrane poration induced by ultrasound exposure: implication for drug delivery. J Control Release 2005;104:213-222.
11.
Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH: Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci USA 1997;94:1562-1567.
12.
Bommannan D, Menon GK, Okuyama H, Elias PM, Guy RH: Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 1992;9:1043-1047.
13.
Gay CL, Guy RH, Golden GM, Mak VHW, Francoeur ML: Characterization of low-temperature (i.e. <65°C) lipid transitions in human stratum corneum. J Invest Dermatol 1994;103:233-239.
14.
Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H: Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004;21:1818-1825.
15.
Bommannan D, Potts RO, Guy RH: Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J Control Release 1991;16:299-304.
16.
Delgado-Charro MB, Guy RH: Characterization of convective solvent flow during iontophoresis. Pharm Res 1994;11:929-935.
17.
Bommannan D, Okuyama H, Stauffer P, Guy RH: Sonophoresis. I. The use of high-frequency ultrasound to enhance transdermal drug delivery. Pharm Res 1992;9:559-564.
18.
Marro D, Guy RH, Delgado-Charro MB: Characterization of the iontophoretic permselectivity properties of human and pig skin. J Control Release 2001;70:213-217.
19.
Kalia YN, Nonato LB, Lund CH, Guy RH: Development of skin barrier function in premature infants. J Invest Dermatol 1998;111:320-326.
20.
Kim A, Green PG, Rao G, Guy RH: Convective solvent flow across the skin during iontophoresis. Pharm Res 1993;10:1315-1320.
21.
Marro D, Kalia YN, Delgado-Charro MB, Guy RH: Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 2001;18:1701-1708.
22.
Rao G, Guy RH, Glikfeld P, LaCourse WR, Leung L, Tamada J, Potts RO, Azimi N: Reverse iontophoresis: noninvasive glucose monitoring in vivo in humans. Pharm Res 1995;12:1869-1873.
23.
Guy RH, Hadgraft J. Mathematical models in percutaneous absorption; in Maibach HI, Lowe NJ (eds): Models in Dermatology. Basel, Karger, 1985, vol 2, pp 170-177.
24.
Guy RH, Hadgraft J: Physicochemical interpretation of the pharmacokinetics of percutaneous absorption. J Pharmacokinet Biopharm 1983;11:189-203.
25.
Guy RH, Hadgraft J, Maibach HI: A pharmacokinetic model for percutaneous absorption. Int J Pharm 1982;11:119-129.
26.
Guy RH, Hadgraft J: Prediction of drug disposition kinetics in skin and plasma following topical administration. J Pharm Sci 1984;73:883-887.
27.
Guy RH, Hadgraft J: Transdermal drug delivery: a simplified pharmacokinetic approach. Int J Pharm 1985;24:267-274.
28.
Guy RH, Hadgraft J: Pharmacokinetic interpretation of the plasma levels of clonidine following transdermal delivery. J Pharm Sci 1985;74:1016-1018.
29.
Guy RH, Hadgraft J: The prediction of plasma levels of drugs following transdermal application. J Control Release 1985;1:177-182.
30.
Evans N, Guy RH, Hadgraft J: Transdermal drug delivery to neonates. Int J Pharm 1985;24:259-265.
31.
Guy RH, Hadgraft J: Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine and timolol. Int J Pharm 1986;32:159-163.
32.
Guy RH, Hadgraft J: A theoretical description relating skin penetration to the thickness of the applied medicament. Int J Pharm 1980;6:321-332.
33.
Guy RH, Hadgraft J, Kellaway IW, Taylor M: Calculations of drug release rates from particles. Int J Pharm 1982;11:199-207.
34.
Guy RH, Hadgraft J: Rate control in transdermal drug delivery? Int J Pharm 1992;82:R1-R6.
35.
Guy RH, Hadgraft J: Physicochemical aspects of percutaneous penetration and its enhancement. Pharm Res 1988;5:753-758.
36.
Green PG, Guy RH, Hadgraft J: In vitro and in vivo enhancement of skin permeation with oleic and lauric acids. Int J Pharm 1988;48:103-111.
37.
Surber C, Wilhelm KP, Hori M, Maibach HI, Guy RH: Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharm Res 1990;7:1320-1324.
38.
Potts RO, Mak VH, Guy RH, Francoeur ML: Strategies to enhance permeability via stratum corneum lipid pathways. Adv Lipid Res 1991;24:173-210.
39.
Mak VHW, Potts RO, Guy RH: Oleic acid concentration and effect in human stratum corneum: non-invasive determination by attenuated total reflectance infrared spectroscopy in vivo. J Control Release 1990;12:67-75.
40.
Mak VHW, Potts RO, Guy RH: Percutaneous penetration enhancement in vivo measured by attenuated total reflectance infrared spectroscopy. Pharm Res 1990;7:835-841.
41.
Potts RO, Golden GM, Francoeur ML, Mak VHW, Guy RH: Mechanism and enhancement of solute transport across the stratum corneum. J Control Release 1991;15:249-260.
42.
Mak VHW, Potts RO, Guy RH: Does hydration affect intercellular lipid organization in the stratum corneum? Pharm Res 1991;8:1064-1065.
43.
Higo N, Naik A, Bommannan DB, Potts RO, Guy RH: Validation of reflectance infrared spectroscopy as a quantitative method to measure percutaneous absorption in vivo. Pharm Res 1993;10:1500-1506.
44.
Kalia YN, Alberti I, Sekkat N, Curdy C, Naik A, Guy RH: Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharm Res 2000;17:1148-1150.
45.
Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH: In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Release 2001;71:319-327.
46.
Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH: Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 2001;219:11-19.
47.
Alberti I, Kalia YN, Naik A, Guy RH: Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res 2001;18:1472-1475.
48.
Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH: Ibuprofen transport into and through skin from topical formulations: In vitro-in vivo comparison. J Invest Dermatol 2007;127:135-142.
49.
Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH: Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest Dermatol 2007;127:887-894.
50.
Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH: Effect of propylene glycol on ibuprofen absorption into human skin in vivo. J Pharm Sci 2008;97:185-197.
51.
Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH: Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man. Pharm Res 2006;23:1850-1856.
52.
Sekkat N, Kalia YN, Guy RH: Biophysical study of porcine ear skin in vitro and its comparison to human skin in vivo. J Pharm Sci 2002;91:2376-2381.
53.
Reddy MB, Guy RH, Bunge AL: Does epidermal turnover reduce percutaneous penetration? Pharm Res 2000;17:1414-1419.
54.
Nicoli S, Bunge AL, Delgado-Charro MB, Guy RH: Dermatopharmacokinetics: factors influencing drug clearance from the stratum corneum. Pharm Res 2009;26:865-871.
55.
Reddy MB, Stinchcomb AL, Guy RH, Bunge AL: Determining dermal absorption parameters in vivo from tape strip data. Pharm Res 2002;19:292-298.
56.
N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL: Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res 2009;26:316-328.
57.
Wiedersberg S, Leopold CS, Guy RH: Dermatopharmacokinetics of betamethasone 17- valerate: influence of formulation viscosity and skin surface cleaning procedure. Eur J Pharm Biopharm 2009;71:362-366.
58.
Mohammed D, Yang Q, Guy RH, Matts PJ, Hadgraft J, Lane ME: Comparison of gravimetric and spectroscopic approaches to quantify stratum corneum removed by tape-stripping. Eur J Pharm Biopharm 2012;82:171-174.
59.
Russell LM, Guy RH: Novel imaging method to quantify stratum corneum in dermatopharmacokinetic studies. Pharm Res 2012;29:2389- 2397.
60.
Russell LM, Guy RH: Novel imaging method to quantify stratum corneum in dermatopharmacokinetic studies: proof-of-concept with acyclovir formulations. Pharm Res 2012;29:3362-3372.
61.
Glikfeld P, Cullander C, Hinz RS, Guy RH: A new system for in vitro studies of iontophoresis. Pharm Res 1988;5:443-446.
62.
Glikfeld P, Hinz RS, Guy RH: Noninvasive sampling of biological fluids by iontophoresis. Pharm Res 1989;6:988-990.
63.
Rao G, Glikfeld P, Guy RH: Reverse iontophoresis: Development of a noninvasive approach for glucose monitoring. Pharm Res 1993;10:1751-1755.
64.
Guy RH, Rao G. Glikfeld P, Cullander C, Hinz RS: Method for the iontophoretic non-invasive determination of the in vivo concentration level of glucose. US Patent No 5730714. 1998. http://xrint.com/patents/us.
65.
Merino V, López A, Hochstrasser D, Guy RH: Noninvasive sampling of phenylalanine by reverse iontophoresis. J Control Release 1999;61:65-69.
66.
Sieg A, Guy RH, Delgado-Charro MB: Electroosmosis in transdermal iontophoresis: implications for noninvasive and calibration-free glucose monitoring. Biophys J 2004;87:3344-3350.
67.
Sieg A, Guy RH, Delgado-Charro MB: Noninvasive glucose monitoring by reverse iontophoresis in vivo: application of the internal standard concept. Clin Chem 2004;50:1383-1390.
68.
Sieg A, Guy RH, Delgado-Charro MB: Reverse iontophoresis for noninvasive glucose monitoring: the internal standard concept. J Pharm Sci 2003;92:2295-2302.
69.
Sieg A, Guy RH, Delgado-Charro MB: Simultaneous extraction of urea and glucose by reverse iontophoresis in vivo. Pharm Res 2004;21:1805-1810.
70.
Sieg A, Jeanneret F, Fathi M, Hochstrasser D, Rudaz S, Veuthey JL, Guy RH, Delgado-Charro MB: Extraction of amino acids by reverse iontophoresis in vivo. Eur J Pharm Biopharm 2009;72:226-231.
71.
Sieg A, Jeanneret F, Fathi M, Hochstrasser D, Rudaz S, Veuthey JL, Guy RH, Delgado-Charro MB: Extraction of amino acids by reverse iontophoresis: simulation of therapeutic monitoring in vitro. Eur J Pharm Biopharm 2008;70:908-913.
72.
Nixon S, Sieg A, Delgado-Charro MB, Guy RH: Reverse iontophoresis of L-lactate: in vitro and in vivo studies. J Pharm Sci 2007;96:3457-3465.
73.
Leboulanger B, Aubry JM, Bondolfi G, Guy RH, Delgado-Charro MB: Lithium monitoring by reverse iontophoresis in vivo. Clin Chem 2004;50:2091-2100.
74.
Leboulanger B, Fathi M, Guy RH, Delgado-Charro MB: Reverse iontophoresis as a noninvasive tool for lithium monitoring and pharmacokinetic profiling. Pharm Res 2004;21:1214-1222.
75.
Leboulanger B, Guy RH, Delgado-Charro MB: Non-invasive monitoring of phenytoin by reverse iontophoresis. Eur J Pharm Sci 2004;22:427-433.
76.
Delgado-Charro MB, Guy RH: Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring. Pharm Res 2003;20:1508-1513.
77.
Bouissou CC, Sylvestre JP, Guy RH, Delgado-Charro MB: Reverse iontophoresis of amino acids: identification and separation of stratum corneum and subdermal sources in vitro. Pharm Res 2009;26:2630-2638.
78.
Sekkat N, Naik A, Kalia YN, Glikfeld P, Guy RH: Reverse iontophoretic monitoring in premature neonates: feasibility and potential. J Control Release 2002;81:83-89.
79.
Sylvestre JP, Bouissou CC, Guy RH, Delgado-Charro MB: Extraction and quantification of amino acids in human stratum corneum in vivo. Br J Dermatol 2010;163:458-465.
80.
Wascotte V, Delgado-Charro MB, Rozet E, Wallemacq P, Hubert P, Guy RH, Préat V: Monitoring of urea and potassium by reverse iontophoresis in vitro. Pharm Res 2007;24:1131-1137.
81.
Wascotte V, Rozet E, Salvaterra A, Hubert P, Jadoul M, Guy RH, Préat V: Non-invasive diagnosis and monitoring of chronic kidney disease by reverse iontophoresis of urea in vivo. Eur J Pharm Biopharm 2007;69:1077-1082.
82.
Wascotte V, Caspers P, De Sterke J, Jadoul M, Guy RH, Préat V: Assessment of the ‘skin reservoir' of urea by confocal Raman microspectroscopy and reverse iontophoresis in vivo. Pharm Res 2007;24:1897-1901.
83.
Yang Q: Application of Biophysics and Bioengineering to the Assessment of Skin Barrier Function; PhD thesis, University of Bath, 2011.
84.
Green P, Shroot B, Bernerd F, Pilgrim WR, Guy RH: In vitro and in vivo iontophoresis of a tripeptide across nude rat skin. J Control Release 1992;20:209-218.
85.
Green PG, Hinz RS, Cullander C, Yamane G, Guy RH: Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res 1991;8:1113-1120.
86.
Green PG, Hinz RS, Kim A, Cullander C, Yamane G, Szoka FC, Guy RH: Transdermal iontophoresis of amino acids and peptides in vitro. J Control Release 1992;21:187-190.
87.
Green PG, Hinz RS, Szoka FC, Guy RH: Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991;8:1121-1127.
88.
Langkjær L, Brange J, Grodsky GM, Guy RH: Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Control Release 1998;51:47-56.
89.
Delgado-Charro MB, Guy RH: Characterization of convective solvent flow during iontophoresis. Pharm Res 1994;11:929-935.
90.
Delgado-Charro MB, Guy RH: Iontophoretic delivery of nafarelin across the skin. Int J Pharm 1995;117:165-172.
91.
Hirvonen J, Guy RH: Transdermal iontophoresis: modulation of electroosmosis by polypeptides. J Control Release 1998;50:283-289.
92.
Hirvonen J, Kalia YN, Guy RH: Transdermal delivery of peptides by iontophoresis. Nat Biotechnol 1996;14:1710-1713.
93.
Santi P, Guy RH: Reverse iontophoresis - parameters determining electroosmotic flow. I. pH and ionic strength. J Control Release 1996;38:159-165.
94.
Santi P, Guy RH: Reverse iontophoresis: parameters determining electro-osmotic flow. II. Electrode chamber formulation. J Control Release 1996;42:29-36.
95.
Hirvonen J, Guy RH: Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res 1997;14:1258-1263.
96.
Turner NG, Ferry L, Price M, Cullander C, Guy RH: Iontophoresis of poly-L-lysines: the role of molecular weight? Pharm Res 1997;14:1322-1331.
97.
Turner NG, Guy RH: Iontophoretic transport pathways: dependence on penetrant physicochemical properties. J Pharm Sci 1997;86:1385-1389.
98.
Turner NG, Guy RH: Visualization and quantitation of iontophoretic pathways using confocal microscopy. J Invest Dermatol Symp Proc 1998;3:136-142.
99.
Oh SY, Guy RH: Effects of iontophoresis on the electrical properties of human skin in vivo. Int J Pharm 1995;124:137-142.
100.
Oh SY, Leung L, Bommannan D, Guy RH, Potts RO: Effect of current, ionic strength and temperature on the electrical properties of skin. J Control Release 1993;27:115-125.
101.
Kalia YN, Guy RH: The electrical characteristics of human skin in vivo. Pharm Res 1995;12:1605-1613.
102.
Kalia YN, Nonato LB, Guy RH: The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and transepidermal water loss. Pharm Res 1996;13:957-960.
103.
Kalia YN, Guy RH: Interaction between penetration enhancers and iontophoresis: effect on human skin impedance in vivo. J Control Release 1997;44:33-42.
104.
Kalia YN, Nonato LB, Lund CH, Guy RH: Development of skin barrier function in premature infants. J Invest Dermatol 1998;111:320-326.
105.
Marro D, Kalia YN, Delgado-Charro MB, Guy RH: Optimizing iontophoretic drug delivery: Identification and distribution of the charge-carrying species. Pharm Res 2001;18:1709-1713.
106.
Merino V, López A, Kalia YN, Guy RH: Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil. Pharm Res 1999;16:758-761.
107.
Lopez RFV, Bentley MVLB, Delgado-Charro MB, Guy RH: Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharm Res 2001;18:311-315.
108.
Lopez RFV, Bentley MVLB, Delgado-Charro MB, Guy RH: Optimization of aminolevulinic acid delivery by iontophoresis. J Control Release 2003;88:65-70.
109.
Lopez RFV, Bentley MVLB, Delgado-Charro MB, Salomon D, Van Den Bergh H, Lange N, Guy RH: Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol 2003;77:304-308.
110.
Mudry B, Carrupt PA, Guy RH, Delgado-Charro MB: Quantitative structure-permeation relationship for iontophoretic transport across the skin. J Control Release 2007;122:165-172.
111.
Mudry B, Guy RH, Delgado-Charro MB: Prediction of iontophoretic transport across the skin. J Control Release 2006;111:362-367.
112.
Mudry B, Guy RH, Delgado-Charro MB: Electromigration of ions across the skin: Determination and prediction of transport numbers. J Pharm Sci 2006;95:561-569.
113.
Mudry B, Guy RH, Delgado-Charro MB: Transport numbers in transdermal iontophoresis. Biophys J 2006;90:2822-2830.
114.
Schuetz YB, Carrupt PA, Naik A, Guy RH, Kalia YN: Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 2006;29:53-59.
115.
Schuetz YB, Naik A, Guy RH, Kalia YN: Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur J Pharm Sci 2005;26:429-437.
116.
Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN: Transdermal iontophoretic delivery of triptorelin in vitro. J Pharm Sci 2005;94:2175-2182.
117.
Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN: Transdermal iontophoretic delivery of vapreotide acetate across porcine skin in vitro. Pharm Res 2005;22:1305-1312.
118.
Abla N, Geiser L, Mirgaldi M, Naik A, Veuthey JL, Guy RH, Kalia YN: Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility. J Pharm Sci 2005;94:2667-2675.
119.
Abla N, Naik A, Guy RH, Kalia YN: Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. J Control Release 2005;108:319-330.
120.
Abla N, Naik A, Guy RH, Kalia YN: Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis. Pharm Res 2005;22:2069-2078.
121.
Abla N, Naik A, Guy RH, Kalia YN: Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery. Pharm Res 2006;23:1842-1849.
122.
Wu X, Landfester K, Musyanovych A, Guy RH: Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-123.
123.
Wu X, Price GJ, Guy RH: Disposition of nanoparticles and an associated lipophilic permeant following topical application to the skin. Mol Pharm 2009;6:1441-1448.
124.
Campbell CSJ, Contreras-Rojas LR, Delgado-Charro MB, Guy RH: Objective assessment of nanoparticle disposition in mammalian skin after topical exposure. J Control Release 2012;162:201-207.
125.
Saar BG, Contreras-Rojas LR, Xie XS, Guy RH: Imaging drug delivery to skin with stimulated Raman scattering microscopy. Mol Pharm 2011;8:969-975.
126.
Nonato LB, Kalia YN, Naik A, Lund CH, Guy RH: The development of skin barrier function in the neonate. J Toxicol Cutan Ocul 2001;20:335-366.
127.
Sekkat N, Kalia YN, Guy RH: Development of an in vitro model for premature neonatal skin: biophysical characterization using transepidermal water loss. J Pharm Sci 2004;93:2936-2940.
128.
Tsang M, Guy RH: Effect of aqueous cream BP on human stratum corneum in vivo. Br J Dermatol 2010;163:954-958.
129.
Kalia YN, Naik A, Garrison J, Guy RH: Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;56:619-658.
130.
Mehier-Humbert S, Guy RH: Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 2005;57:33-753.
131.
Moser K, Kriwet K, Naik A, Kalia YN, Guy RH: Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001;52:103-112.
132.
Naik A, Kalia YN, Guy RH: Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Tech Today 2000;3:318-326.
133.
Guy RH: Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13:1765-1769.
134.
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, MacGowan AL, Tazi-Ahnini R, Ward SJ: Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.